Beckman Coulter Achieves CE Mark for Early Sepsis Indicator

Beckman Coulter’s early sepsis indicator device, a hematology-based test, received CE Mark certification.

The new test will be made commercially available on the company’s recently launched DxH 900 hematology analyzer. The indicator uses the analyzer’s technology to characterize cells in their near-native states.

The hematology-based test is meant to alert emergency department clinicians about the possibility or risk of developing sepsis as part of a routine complete blood count.